HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system

この資料はクリエイティブ・コモンズ・ライセンスの下で公開されています。

フルテキスト
rrx083.pdf1.06 MBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/70251

タイトル: Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system
著者: Nishioka, Kentaro 著作を一覧する
Prayongrat, Anussara 著作を一覧する
Ono, Kota 著作を一覧する
Onodera, Shunsuke 著作を一覧する
Hashimoto, Takayuki 著作を一覧する
Katoh, Norio 著作を一覧する
Inoue, Tetsuya 著作を一覧する
Kinoshita, Rumiko 著作を一覧する
Yasuda, Koichi 著作を一覧する
Mori, Takashi 著作を一覧する
Onimaru, Rikiya 著作を一覧する
Shirato, Hiroki 著作を一覧する
Shimizu, Shinichi 著作を一覧する
キーワード: spot-scanning
synchrotron-based
proton beam therapy
safety
toxicity
adverse event
発行日: 2018年 3月
出版者: Oxford University Press
誌名: Journal of Radiation Research
巻: 59
号: suppl_1
開始ページ: i63
終了ページ: i71
出版社 DOI: 10.1093/jrr/rrx083
抄録: This is a report of a single-institution prospective study evaluating the safety of a spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy (PBT) system. Data collection was performed for 56 patients with 59 treatment sites who received proton beam therapy at Hokkaido University Hospital between March 2014 and July 2015. Forty-one patients were male and 15 were female. The median age was 66 years. The primary lesion sites were prostate (n = 17), bone/soft tissue (n = 10), liver (n = 7), lung (n = 6), central nervous system (n = 5), colon (n = 2), pancreas (n = 2), kidney (n = 2) and others (n = 5). Chemotherapy was administered in 11 patients. The prescribed total dose was from 20 to 76 GyE (Radiobiological equivalent dose, RBE = 1.1), with the median dose of 65 GyE in 4 to 35 fractions. No PBT-related Common Terminology Criteria for Adverse Events Grade 4 or 5 toxicities were observed; the incidence of early PBT-related Grade 4 adverse events was 0% (95% confidence interval 0 to 6.38%). The most common Grade 3 toxicities were hematologic toxicity (12.5%) unlikely to be related to the PBT. One patient developed a left femoral neck fracture (Grade 3) at 14.5 months after PBT for chondrosarcoma of the left pelvis. The pathological findings showed no other malignancies, suggesting that it was possibly related to the PBT. In conclusion, the spot-scanning dedicated, synchrotron-based PBT system is feasible, but further studies on its long-term safety and efficacy are warranted.
資料タイプ: article
URI: http://hdl.handle.net/2115/70251
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 西岡 健太郎

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学